Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02948959 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Dupilumab in Children With Uncontrolled Asthma
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 408
- Enrollment target
NCT02948959 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 408 participants.
The verdict
NCT02948959, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 408 participants
- Enrollment target
Study Summary
Primary Objective: To evaluate the efficacy of dupilumab in children 6 to less than (\<) 12 years of age with uncontrolled persistent asthma. Secondary Objective: To evaluate in children 6 to \<12 years of age with uncontrolled persistent asthma: * The safety and tolerability of dupilumab. * The evaluate the effect of dupilumab in improving participant reported outcomes including health related quality of life. * The dupilumab systemic exposure and incidence of anti-drug antibodies. * The evaluate the association between dupilumab treatment and pediatric immune responses to vaccines: any vaccination for tetanus, diphtheria, pertussis and/or seasonal trivalent/quadrivalent influenza vaccine.
Interventions
- DRUG Placebo
- DRUG Dupilumab
- DRUG Asthma Controller Therapies
- DRUG Asthma Reliever Therapies
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 408 participants |
| Start Date | 2017-04-21 |
| Est. Completion | 2020-08-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02948959
The ClinicalTrials.gov registry entry for NCT02948959 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 408 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02948959 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02948959 about?
NCT02948959 is a clinical study titled "Evaluation of Dupilumab in Children With Uncontrolled Asthma". Primary Objective: To evaluate the efficacy of dupilumab in children 6 to less than (\<) 12 years of age with uncontrolled persistent asthma. Secondary Objective: To evaluate in children 6 to \<12 years of age with uncontrolled persistent asthma: * The safety and tolerability of dupilumab. * The...
What is the current status of trial NCT02948959?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 408 participants. The study started on 2017-04-21. Estimated completion is 2020-08-26.
What interventions are being tested in trial NCT02948959?
The interventions under investigation include: Placebo (DRUG), Dupilumab (DRUG), Asthma Controller Therapies (DRUG), Asthma Reliever Therapies (DRUG).
Who is sponsoring clinical trial NCT02948959?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.